Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial

References

• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392:245–52.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Witmer-Pack M, Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol. 1993; 329:1–9.
   PubMedGoogle Scholar
• Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994; 180:83–93.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994; 179:1109–18.
   PubMed Web of Science ®Google Scholar
• Caux C, Dezutter DC, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature. 1992; 360:258–61.
   PubMed Web of Science ®Google Scholar
• Siena S, Di Nicola M, Bregni M, Mortarini R, Anichini A, Lombardi L, et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol. 1995; 23:1463–71.
   PubMed Web of Science ®Google Scholar
• Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol. 2005; 175:1373–81.
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Ponsaerts P, Berneman ZN. mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther. 2007; 9:423–31.
   PubMed Web of Science ®Google Scholar
• Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN, et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia. 2005; 19:1863–71.
   Google Scholar
• Miwa H, Beran M, Saunders GF. Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia. 1992; 6:405–9.
   PubMed Web of Science ®Google Scholar
• Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, et al. Presence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995; 9:1060–7.
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997; 89:1405–12.
   PubMed Web of Science ®Google Scholar
• Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999; 90:194–204.
   PubMedGoogle Scholar
• Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994; 84:3071–9.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol. 2008; 20:211–20.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003; 102:2892–900.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004; 103:479–85.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005; 106:1154–63.
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002; 100:2132–7.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004; 101:13885–90.
   PubMed Web of Science ®Google Scholar
• Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004; 18:165–6.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008; 111:236–42.
   PubMed Web of Science ®Google Scholar
• Barratt-Boyes SM, Figdor CG. Current issues in delivering DCs for immunotherapy. Cytotherapy. 2004; 6:105–10.
   PubMed Web of Science ®Google Scholar
• Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004; 10:475–80.
   PubMed Web of Science ®Google Scholar
• Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol. 2006; 133:152–7.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Choi BH, Kang HK, Kim SK, Nam JH, Yang DH, et al. Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients. Leuk Res. 2008; 32:1653–60.
   Google Scholar
• Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001; 98:49–56.
   PubMed Web of Science ®Google Scholar
• Schaft N, Dorrie J, Thumann P, Beck VE, Muller I, Schultz ES, et al. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol. 2005; 174:3087–97.
   PubMed Web of Science ®Google Scholar
• Cools N, Van Tendeloo VF, Smits EL, Lenjou M, Nijs G, Van Bockstaele DR, et al. Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells. J Cell Mol Med. 2008; 12:690–700.
   PubMed Web of Science ®Google Scholar
• Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol. 1999; 162:3231–6.
   PubMed Web of Science ®Google Scholar
• Vieira PL, De Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000; 164:4507–12.
   PubMed Web of Science ®Google Scholar
• Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods. 2002; 268:131–40.
   PubMed Web of Science ®Google Scholar
• Erdmann M, Dorrie J, Schaft N, Strasser E, Hendelmeier M, Kampgen E, et al. Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection. J Immunother. 2007; 30:663–74.
   PubMed Web of Science ®Google Scholar
• Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, et al. Generation of large numbers of dendritic cells in a closed system using cell factories. J Immunol Methods. 2002; 264:135–51.
   PubMed Web of Science ®Google Scholar
• Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. Immunobiology. 2006; 211:677–85.
   Google Scholar
• Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997; 27:3135–42.
   PubMed Web of Science ®Google Scholar
• Markovic SN, Dietz AB, Greiner CW, Maas ML, Butler GW, Padley DJ, et al. Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl Med. 2006; 4:35–47.
   PubMed Web of Science ®Google Scholar
• Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, et al. Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy. 2004; 6:563–70.
   PubMed Web of Science ®Google Scholar
• Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application [published erratum appears in J Immunol Methods 1999;224:211]. J Immunol Methods. 1999; 223:1–15.
   PubMed Web of Science ®Google Scholar
• Pickl WF, Majdic O, Kohl P, Stockl J, Riedl E, Scheinecker C, et al. Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J Immunol. 1996; 157:3850–9.
   PubMed Web of Science ®Google Scholar
• Faradji A, Bohbot A, Schmitt GM, Siffert JC, Dumont S, Wiesel ML, et al. Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients. J Immunol Methods. 1994; 174:297–309.
   PubMed Web of Science ®Google Scholar
• Rouard H, Leon A, De Reys S, Taylor L, Logan J, Marquet J, et al. A closed and single-use system for monocyte enrichment: potential for dendritic cell generation for clinical applications. Transfusion. 2003; 43:481–7.
   PubMed Web of Science ®Google Scholar
• Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, et al. Efficient elutriation of monocytes within a closed system (Elutra™) for clinical-scale generation of dendritic cells. J Immunol Methods. 2005; 298:61–72.
   PubMed Web of Science ®Google Scholar
• Adamson L, Palmborg A, Svensson A, Lundqvist A, Hansson M, Kiessling R, et al. Development of a technology platform for large-scale clinical grade production of DC. Cytotherapy. 2004; 6:363–71.
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Adamson L, Palma M, Osterborg A, Pisa P, Choudhury A, et al. Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors. Cytotherapy. 2006; 8:318–26.
   PubMed Web of Science ®Google Scholar
• Babatz J, Rollig C, Oelschlagel U, Zhao S, Ehninger G, Schmitz M, et al. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. J Hematother Stem Cell Res. 2003; 12:515–23.
   PubMedGoogle Scholar
• Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, et al. Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy. 2004; 6:563–70.
   PubMed Web of Science ®Google Scholar
• Felzmann T, Witt V, Wimmer D, Ressmann G, Wagner D, Paul P, et al. Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection. Cytotherapy. 2003; 5:391–8.
   PubMed Web of Science ®Google Scholar
• Meyer-Wentrup F, Burdach S. Efficacy of dendritic cell generation for clinical use: recovery and purity of monocytes and mature dendritic cells after immunomagnetic sorting or adherence selection of CD14+ starting populations. J Hematother Stem Cell Res. 2003; 12:289–99.
   PubMedGoogle Scholar
• Breckpot K, Corthals J, Heirman C, Bonehill A, Michiels A, Tuyaerts S, et al. Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells. Hum Gene Ther. 2004; 15:562–73.
   Google Scholar
• Elkord E, Williams PE, Kynaston H, Rowbottom AW. Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology. 2005; 114:204–12.
   PubMed Web of Science ®Google Scholar
• Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol. 2006; 28:855–61.
   PubMed Web of Science ®Google Scholar
• Fratantoni JC, Dzekunov S, Singh V, Liu LN. A non-viral gene delivery system designed for clinical use. Cytotherapy. 2003; 5:208–10.
   Google Scholar